Gallbladder cancer laboratory tests

Revision as of 04:05, 23 January 2018 by Gunnam (talk | contribs)
Jump to navigation Jump to search

Gallbladder cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gallbladder cancer from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Palliative Treatment

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gallbladder cancer laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gallbladder cancer laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gallbladder cancer laboratory tests

CDC on Gallbladder cancer laboratory tests

Gallbladder cancer laboratory tests in the news

Blogs on Gallbladder cancer laboratory tests

Directions to Hospitals Treating Gallbladder cancer

Risk calculators and risk factors for Gallbladder cancer laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]

Overview

There are no diagnostic laboratory findings associated with gallbladder cancer

Laboratory tests[1] [2]

  • Laboratory studies are usually nondiagnostic
  • An elevated alkaline phosphatase or serum bilirubin can be associated with bile duct obstruction.
  • Serum tumor markers including carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 are frequently elevated, but they're no longer diagnostically useful because they lack specificity and sensitivity.
  • CA 242 is a tumor marker for gallbladder cancer and performs better than CEA and CA 19-9
  • However, if a tumor marker is observed to be elevated preoperatively, serial assay after resection may useful resource within the analysis of chronic or recurrent disease.

References

  1. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA, Rios-Dalenz J, Iliopoulos D, Soloway RD (1990). "Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer?". Int. J. Cancer. 45 (5): 821–4. PMID 2335386.
  2. Rana S, Dutta U, Kochhar R, Rana SV, Gupta R, Pal R, Jain K, Srinivasan R, Nagi B, Nain CK, Singh K (2012). "Evaluation of CA 242 as a tumor marker in gallbladder cancer". J Gastrointest Cancer. 43 (2): 267–71. doi:10.1007/s12029-011-9288-7. PMID 21573879.


Template:WikiDoc Sources